What is the recommended treatment regimen for giant‑cell (temporal) arteritis?

Treatment of Temporal Arteritis (Giant Cell Arteritis)

Start high-dose oral prednisone 40–60 mg daily (or 1 mg/kg/day, maximum 60 mg) immediately upon clinical suspicion—even before biopsy confirmation—to prevent irreversible vision loss, which occurs in 14–50% of untreated patients. 1, 2, 3

Immediate Management Based on Clinical Presentation

For Patients WITHOUT Visual Symptoms or Threatened Vision Loss

• Initiate oral prednisone 40–60 mg daily (or 1 mg/kg/day, maximum 60 mg) as a single morning dose immediately upon clinical suspicion. 1, 2, 3
• Do not delay treatment while awaiting temporal artery biopsy or imaging results; irreversible blindness can occur within hours to days. 1, 2, 3
• Arrange temporal artery biopsy within 2 weeks of starting glucocorticoids; histopathologic changes remain detectable for 1–2 weeks after steroid initiation. 1, 2
• Obtain a long-segment biopsy (≥1 cm) to minimize false-negative results from skip lesions, which occur in approximately 10% of cases. 1, 2

For Patients WITH Visual Symptoms or Threatened Vision Loss

• Administer intravenous methylprednisolone 500–1000 mg daily for 3 consecutive days, then transition to high-dose oral prednisone 40–60 mg daily. 1, 2, 3
• Begin IV therapy immediately—do not wait for biopsy confirmation or specialist consultation. 1, 2
• The rationale for IV pulse therapy in vision-threatening disease is to achieve both genomic and rapid non-genomic glucocorticoid effects, though evidence quality is limited to retrospective data. 1

Critical pitfall: Avoid routine IV pulse glucocorticoids in patients without visual symptoms, as they increase infection risk in elderly patients without proven superiority over oral therapy. 2, 4, 5

First-Line Adjunctive Therapy: Tocilizumab

Add tocilizumab to glucocorticoids at the time of diagnosis for all GCA patients to reduce relapse rates, minimize cumulative glucocorticoid exposure, and facilitate faster steroid tapering. 1, 2, 3

Tocilizumab Dosing (FDA-Approved)

• Subcutaneous: 162 mg once weekly (preferred regimen). 6
• Alternative subcutaneous: 162 mg every other week may be prescribed based on clinical considerations. 6
• Intravenous: 6 mg/kg every 4 weeks (maximum 600 mg per infusion). 6
• When transitioning from IV to subcutaneous, administer the first subcutaneous dose instead of the next scheduled IV dose. 6

Alternative Steroid-Sparing Agents

• Methotrexate may be used when tocilizumab is contraindicated (e.g., recurrent infections, history of gastrointestinal perforations or diverticulitis, cost constraints). 1, 2, 3
• Evidence for methotrexate is less robust than for tocilizumab, particularly for relapsing disease with cranial ischemic symptoms. 1
• Abatacept can be considered if tocilizumab and methotrexate are not effective. 1

Glucocorticoid Tapering Strategy

Maintain the initial high dose (40–60 mg daily) for approximately 1 month until symptoms resolve and inflammatory markers (ESR/CRP) normalize, then begin gradual taper guided by clinical response—not a fixed calendar. 1, 2, 3

Structured Taper Schedule

• Target 15–20 mg/day by 2–3 months after achieving remission. 1, 2
• Target 10–15 mg/day by 3 months. 2, 3
• Target ≤5 mg/day by 12 months if disease is controlled. 1, 2, 3
• Total treatment duration: Most patients require 1–2 years of glucocorticoid therapy; some may require longer courses. 2, 3

Tapering Principles

• Guide tapering by clinical symptoms and normalization of ESR/CRP, not by laboratory values alone. 1, 2, 3
• Use daily dosing throughout the taper; avoid alternate-day schedules, which increase relapse risk. 1, 2
• Relapses occur in 34–75% of patients during steroid tapering, with variation due to different definitions and protocols. 1, 2
• A 26-week taper protocol showed similar relapse rates to a 52-week protocol until week 15; faster reduction after that point increased relapse risk. 1

Critical pitfall: Do not rely solely on inflammatory markers to guide tapering; isolated ESR/CRP elevation without clinical symptoms warrants observation and monitoring rather than dose escalation. 2, 3

Management of Disease Relapse

Major Relapse (Cranial Ischemic Symptoms)

• Increase prednisone to 40–60 mg/day immediately. 1, 2
• Add tocilizumab (preferred over methotrexate for relapsing disease with cranial ischemia). 1, 2, 3

Minor Relapse (Constitutional Symptoms or Polymyalgia Rheumatica Features)

• Modestly increase glucocorticoid dose (5–15 mg/day above the last effective dose). 1
• Slow the taper and consider initiating or optimizing a steroid-sparing agent. 1, 3

Isolated Inflammatory Marker Elevation Without Symptoms

• Clinical observation and monitoring without escalation of immunosuppressive therapy is recommended. 1, 2, 3
• Increase frequency of monitoring rather than treatment intensity. 2

Special Considerations for Large Vessel Involvement

• Obtain baseline noninvasive vascular imaging (MR or CT angiography of neck, chest, abdomen, pelvis) in all newly diagnosed patients to detect extracranial large-vessel involvement. 2, 3
• For patients with active extracranial large vessel involvement, use oral glucocorticoids combined with a non-glucocorticoid immunosuppressive agent (preferably tocilizumab) over glucocorticoids alone. 1, 3
• Periodic imaging is necessary for patients with known large-vessel involvement to assess for aneurysms, stenoses, and stability of lesions. 2, 3
• Patients without large vessel involvement may not require routine repeated imaging. 2

Supportive Care and Monitoring

Bone Protection

• Provide calcium, vitamin D, and bisphosphonates (as indicated) to all patients on long-term glucocorticoids. 2, 3
• Glucocorticoid-related adverse events occur in approximately 86% of patients on long-term therapy. 1, 2

Cardiovascular Protection

• Prescribe low-dose aspirin (75–150 mg/day) for all GCA patients unless contraindicated, to protect against cardiovascular and cerebrovascular events. 3

Regular Monitoring

• At each visit, assess headache, jaw claudication, visual changes, and measure ESR and CRP. 2, 3
• Implement long-term clinical monitoring even in patients who appear to be in remission, as relapses and vascular complications can develop years after diagnosis. 2, 3
• Monitor continuously for glucocorticoid-related adverse effects (infection, osteoporosis, hyperglycemia, hypertension). 2, 3

Common Pitfalls to Avoid

• Never delay high-dose glucocorticoid treatment while awaiting biopsy confirmation, specialist consultation, or imaging; immediate therapy is essential to prevent irreversible vision loss. 1, 2, 3
• Do not use infliximab for GCA, as it is associated with recurrent ocular symptoms and persistent disease activity. 2, 3
• Do not obtain biopsy specimens <1 cm, as skip lesions cause false-negative results in approximately 10% of cases. 1, 2
• Do not rely solely on ESR/CRP for treatment decisions; clinical assessment should take precedence over isolated laboratory elevations. 2, 3
• Avoid rapid steroid withdrawal, as it can lead to disease exacerbation. 3
• Do not use statins specifically for the treatment of GCA; they do not provide clinically significant immunosuppressive effects. 1

Prognosis

• Visual loss occurs in 15–35% of patients with GCA, primarily before initiation of therapy. 2, 3
• Without treatment, the risk of vision loss in the second eye is as high as 50% if one eye is already affected. 2, 3
• Only 4% of patients with visual loss show any visual improvement with high-dose steroid therapy. 4
• 4% of patients develop further visual loss during the first 5 days of high-dose steroid therapy, but none after that period. 4, 5
• Sequential involvement of the fellow eye despite pulse treatment is rare but can occur up to 12 days after treatment initiation, with a median of 2 days. 7